# DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION

> **NIH NIH N43** · MOLECULAR EXPRESS, INC. · 2021 · $569,807

## Abstract

The overall goal of this project is to use VesiVax® platform technology to develop effective immunosimilar formulations of an AS01/AS01b.

## Key facts

- **NIH application ID:** 10470544
- **Project number:** 75N93021C00039-0-9999-1
- **Recipient organization:** MOLECULAR EXPRESS, INC.
- **Principal Investigator:** GARY FUJII
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $569,807
- **Award type:** —
- **Project period:** 2021-08-01 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10470544

## Citation

> US National Institutes of Health, RePORTER application 10470544, DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION (75N93021C00039-0-9999-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10470544. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*